Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 54

1.

The IGF-1/PI3K/Akt pathway prevents expression of muscle atrophy-induced ubiquitin ligases by inhibiting FOXO transcription factors.

Stitt TN, Drujan D, Clarke BA, Panaro F, Timofeyva Y, Kline WO, Gonzalez M, Yancopoulos GD, Glass DJ.

Mol Cell. 2004 May 7;14(3):395-403.

2.

Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy.

Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH, Goldberg AL.

Cell. 2004 Apr 30;117(3):399-412.

3.

Hypertrophy of the heart: a new therapeutic target?

Frey N, Katus HA, Olson EN, Hill JA.

Circulation. 2004 Apr 6;109(13):1580-9. Review.

4.

A small molecular activator of cardiac hypertrophy uncovered in a chemical screen for modifiers of the calcineurin signaling pathway.

Bush E, Fielitz J, Melvin L, Martinez-Arnold M, McKinsey TA, Plichta R, Olson EN.

Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):2870-5. Epub 2004 Feb 19.

5.

MCIP1 overexpression suppresses left ventricular remodeling and sustains cardiac function after myocardial infarction.

van Rooij E, Doevendans PA, Crijns HJ, Heeneman S, Lips DJ, van Bilsen M, Williams RS, Olson EN, Bassel-Duby R, Rothermel BA, De Windt LJ.

Circ Res. 2004 Feb 20;94(3):e18-26. Epub 2004 Jan 22.

6.

Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy.

Wilkins BJ, Dai YS, Bueno OF, Parsons SA, Xu J, Plank DM, Jones F, Kimball TR, Molkentin JD.

Circ Res. 2004 Jan 9;94(1):110-8. Epub 2003 Dec 1.

7.

CHIP activates HSF1 and confers protection against apoptosis and cellular stress.

Dai Q, Zhang C, Wu Y, McDonough H, Whaley RA, Godfrey V, Li HH, Madamanchi N, Xu W, Neckers L, Cyr D, Patterson C.

EMBO J. 2003 Oct 15;22(20):5446-58.

8.

Megaprimer PCR: application in mutagenesis and gene fusion.

Burke E, Barik S.

Methods Mol Biol. 2003;226:525-32. No abstract available.

PMID:
12958540
9.

Control of cardiac growth and function by calcineurin signaling.

Vega RB, Bassel-Duby R, Olson EN.

J Biol Chem. 2003 Sep 26;278(39):36981-4. Epub 2003 Jul 24. Review. No abstract available.

10.

A transgenic mouse model of the ubiquitin/proteasome system.

Lindsten K, Menéndez-Benito V, Masucci MG, Dantuma NP.

Nat Biotechnol. 2003 Aug;21(8):897-902. Epub 2003 Jul 20.

PMID:
12872133
11.
12.

The cardiac mechanical stretch sensor machinery involves a Z disc complex that is defective in a subset of human dilated cardiomyopathy.

Knöll R, Hoshijima M, Hoffman HM, Person V, Lorenzen-Schmidt I, Bang ML, Hayashi T, Shiga N, Yasukawa H, Schaper W, McKenna W, Yokoyama M, Schork NJ, Omens JH, McCulloch AD, Kimura A, Gregorio CC, Poller W, Schaper J, Schultheiss HP, Chien KR.

Cell. 2002 Dec 27;111(7):943-55.

13.

Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy.

van Rooij E, Doevendans PA, de Theije CC, Babiker FA, Molkentin JD, de Windt LJ.

J Biol Chem. 2002 Dec 13;277(50):48617-26. Epub 2002 Sep 10.

14.

Multiple domains of MCIP1 contribute to inhibition of calcineurin activity.

Vega RB, Yang J, Rothermel BA, Bassel-Duby R, Williams RS.

J Biol Chem. 2002 Aug 16;277(33):30401-7. Epub 2002 Jun 12.

15.

The SCF ubiquitin ligase: an extended look.

Jackson PK, Eldridge AG.

Mol Cell. 2002 May;9(5):923-5. Review.

16.

Structure of the Cul1-Rbx1-Skp1-F boxSkp2 SCF ubiquitin ligase complex.

Zheng N, Schulman BA, Song L, Miller JJ, Jeffrey PD, Wang P, Chu C, Koepp DM, Elledge SJ, Pagano M, Conaway RC, Conaway JW, Harper JW, Pavletich NP.

Nature. 2002 Apr 18;416(6882):703-9.

PMID:
11961546
17.

Impaired cardiac hypertrophic response in Calcineurin Abeta -deficient mice.

Bueno OF, Wilkins BJ, Tymitz KM, Glascock BJ, Kimball TF, Lorenz JN, Molkentin JD.

Proc Natl Acad Sci U S A. 2002 Apr 2;99(7):4586-91. Epub 2002 Mar 19.

18.

Targeted inhibition of calcineurin in pressure-overload cardiac hypertrophy. Preservation of systolic function.

Hill JA, Rothermel B, Yoo KD, Cabuay B, Demetroulis E, Weiss RM, Kutschke W, Bassel-Duby R, Williams RS.

J Biol Chem. 2002 Mar 22;277(12):10251-5. Epub 2002 Jan 10.

19.

Genetic alterations that inhibit in vivo pressure-overload hypertrophy prevent cardiac dysfunction despite increased wall stress.

Esposito G, Rapacciuolo A, Naga Prasad SV, Takaoka H, Thomas SA, Koch WJ, Rockman HA.

Circulation. 2002 Jan 1;105(1):85-92.

20.

Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy.

Gomes MD, Lecker SH, Jagoe RT, Navon A, Goldberg AL.

Proc Natl Acad Sci U S A. 2001 Dec 4;98(25):14440-5. Epub 2001 Nov 20.

Supplemental Content

Support Center